Shuttle Pharmaceuticals Holdings,Inc. SHPH 深 滬
已收盤 08-01 16:00:00 美东时间
3.50
-0.150
-4.11%
華盛通- 最 高3.6972
- 今 開3.60
- 成交量 3.00万股
- 最 低 3.3328
- 昨 收 3.65
- 總市值 161.46万
- 52周最高 82.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.00
- 委 比 77.68%
- 總股本 46.13万
- 歷史最高 25252.00
- 量 比 0.79
- 振 幅 9.98%
- 歷史最低 3.1175
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Shuttle Pharmaceuticals COO Resigns Amid Leadership Changes
The latest announcement is out from Shuttle Pharmaceuticals Holdings, Inc. ( ($...
07-31 05:40
Shuttle Pharmaceuticals Has Been Granted U.S Patent Number 12,357,650 Titled "Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With Radiation".
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12357650).pn
07-16 03:59
Shuttle Pharmaceuticals Announces Pricing Of $4.25M Private Placement At A Purchase Price Of $3.60 Per Share
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with
06-21 03:57
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharmaceuticals, a specialty pharmaceutical company focused on improving cancer outcomes for patients undergoing radiation therapy, announced it entered a securities purchase agreement with an accredited investor for total gross proceeds of $4.25 million. The funds will be used for potential acquisitions, marketing, and general corporate purposes. The offering involves issuing 1,180,877 shares of common stock at $3.60 per share, priced at...
06-20 19:55
Shuttle Pharma Board Approves Proposed Reverse Stock Split Of Common Stock At Ratio Of 25-For-1
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with
06-12 20:36
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
Shuttle Pharmaceuticals Holdings, Inc. announces a 1:25 reverse stock split effective June 16, 2025, reducing outstanding shares from 26,210,037 to ~1,048,401. The common stock will continue trading on Nasdaq under "SHPH" with a new CUSIP number, 825693401. The split aims to maintain compliance with Nasdaq listing requirements and strengthen the company's capital structure.
06-12 16:00
Shuttle Pharma Announces The Appointment Of George Scorsis As The Chairman Of The Board Of Directors
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with
06-05 04:04
Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors
Shuttle Pharmaceuticals Holdings, Inc. ("Shuttle Pharma") announced the appointment of George Scorsis as the Chairman of the Board of Directors. With over 25 years of experience in leading companies in regulated industries, Scorsis has served in various executive roles, including President of Mettrum Health Corp., CEO and Director of Liberty Health Sciences, and Chairman of SOL Global Investments Corp. Scorsis commented on his role, emphasizing S...
06-04 20:01
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 79.5% to $0.4...
05-09 20:10
Shuttle Pharmaceuticals Has Been Granted A European Patent Titled "DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION (FOR TREATMENT OF CANCERS, NEUROLOGICAL DISORDERS, & IMMUNOLOGICAL DISORDERS)"
https://data.epo.org/publication-server/publications/pdf?path=2025/19/DOC/EPNWB1/EP21191547NWB1/EP21191547NWB1.pdf
05-07 20:19
